Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in Chinese Patients With Colchicine-resistant Familial Mediterranean Fever
NCT06666335Phase 4Withdrawn
- Sponsor
- Sobi
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Cytokines & Interferons
01
Overview
Phase 4, open-label, single-arm trial of anakinra in Familial Mediterranean fever (FMF), sponsored by Sobi. Primary endpoint: Change from baseline in the number of FMF attacks per month at 6 months. Planned start Mar 2026; status: withdrawn.
02
Drugs
anakinra
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NCT06666335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666335.